But retatrutide functions differently than other popular drugs.
That’s because it’s a triple hormone receptor agonist. Instead of targeting and stimulating just one hormone to help curb appetite and make people feel fuller like GLP- class drugs, retatrutide targets three.
Now, some people are calling retatrutide a “GLP-3.”
However, more research needs to be conducted into their safety – and they are not without risk.
More than 12 percent of patients in the retatrutide drug trial lost so much weight and experienced other “adverse events” that they stopped taking the drug, Eli Lilly said.
And, more than 20 percent of people taking the highest dose of the Eli Lilly drug – 12 milligrams – also had a condition that makes touching the skin painful.